Clinical Trials

Sponsor: Alliance Charitable Foundation

Sponsor Study ID: A012103

Study Title: OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

NCT Number: NCT05812807

Phase: III

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Breast

Study Objectives: To evaluate whether observation results in a non-inferior RFS compared to adjuvant pembrolizumab in early-stage TNBC patients who achieve a pCR after neoadjuvant chemotherapy with pembrolizumab



Study Documents    
(MUSC NetID required for document access)